Group items matching

in title, tags, annotations or url

Thirteen people were arrested following raids at four drug manufacturing units in the Indian states of Gujarat and Rajasthan, resulting in the seizure of mephedrone valued at Rs 230 crore (approximately 22.30 million GBP), according to a news agency report. The Gujarat Anti-Terrorist Squad (ATS) and Narcotics Control Bureau conducted the raids jointly on Friday, prompted by a tip-off received by the ATS indicating that Ahmedabad resident Manoharlal Enani and Kuldeepsinh Rajpurohit from Rajasthan had set up mephedrone manufacturing units, PTI reported on Saturday, quoting an official. As stated in an ATS release obtained by the news agency, the raids were conducted at the units in Sirohi and Jodhpur in Rajasthan and Piplaj village in Gandhinagar and Bhaktinagar industrial area of Amreli district in Gujarat. "The ATS recovered 22.028 kilograms of mephedrone (in solid form) and 124 kilograms of liquid mephedrone, collectively valued at Rs 230 crore(approximately 22.30 million GBP). "Rajpurohit was nabbed during the raid in Gandhinagar and Enani was held from Sirohi," it said.

The General Pharmaceutical Council (GPHC), Royal Pharmaceutical Society (RPS), Company Chemists Association (CCA), Association of Pharmacy Technicians UK (APTUK), National Pharmacy Association (NPA), Guild of Healthcare Pharmacists, Pharmacists' Defence Association (PDA), and Independent Pharmacies Association (IPA) have released a joint statement in response to the far-right riots across the UK. They emphasised their united stance, declaring zero tolerance for racism towards colleagues or the public in any form. The joint statement reads: "We are shocked and saddened by the violent public disorder events in recent days. "We acknowledge how all sectors of the pharmacy profession may be impacted and recognise the challenges that this level of overt aggression can have on people's ability or willingness to live their daily lives. "The pharmacy workforce deserves peace and safety, not fear and harm. We stand united in having a zero tolerance of racism towards our colleagues or the public in whatever form it takes." Meanwhile, Community Pharmacy England (CPE) has expressed concerns that protests and violent disorder in various towns and cities across England may impact the ability of community pharmacies to operate.

Hundreds of workers at pharmaceutical giant GlaxoSmithKline are set to strike over a "derisory" pay offer way below the level of British inflation, a union said on Wednesday (April 20). Unite general secretary Sharon Graham accused GSK of "colossal corporate greed" over an effective pay cut in real terms as Britain experiences its highest inflation in 30 years. GSK said it was "disappointed that the Unite union has taken the decision to strike", adding that the British group "remains committed to… a solution". It said in a statement: "We recognise the impact inflation rates are having on people around the country and are strongly committed to supporting the skilled people who work in GSK manufacturing." About 500 Unite members, or around 13 per cent of GSK's UK manufacturing workforce, voted to strike, the drugs group said. GSK said it had offered a four-percent increase in base salary plus one-off awards.

On World Pharmacists' Day, the Council of the Pharmaceutical Society NI (PSNI) thanked pharmacists working in every sector of pharmacy in Northern Ireland (NI) for their continued service to the public. The theme of this year's International Pharmaceutical Federation's World Pharmacists' Day, (25 September 2022) was 'Pharmacy united in action for a healthier world'. In acknowledgement of the day, Dr. Jim Livingstone, president of the Council of the Pharmaceutical Society NI said: "The theme of this year's World Pharmacists' Day, 'Pharmacy united in action for a healthier world' highlights pharmacy's positive impact on health around the world and seeks to further strengthen solidarity amongst the profession. "In Northern Ireland, pharmacy played a prominent role in primary health care throughout the pandemic and remains the public's most trusted and accessible frontline health care profession. "As pharmacy continues to develop additional services for the public and encompasses broader roles for pharmacists than ever before, it is essential, no matter what pharmacy sector pharmacists practise in, that the Pharmaceutical Society NI's Code (Professional standards of conduct, ethics and performance for pharmacists in Northern Ireland) remains at the core of pharmacists' practice. It is through this adherence to the Code, that pharmacy remains a united profession, providing positive health outcomes for patients and maintaining public trust.

US drugs giant Pfizer will exit its consumer healthcare joint venture with GlaxoSmithKline after the unit is spun off next month, the British drugmaker said Wednesday (June 1). GSK will list the healthcare division on the London stock market on July 18 as it looks to concentrate on the pharmaceutical business, it said in a statement. The London-listed firm currently owns a majority 68 percent of the unit, with Pfizer holding the remainder. "Pfizer intends to exit its 32-percent ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders," GSK said. Covid jab maker Pfizer is seeking to pursue its focus on "innovative medicines and vaccines", it noted. The unit, which will be named Haleon after the demerger, makes products including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

Britain on Monday (January 10) put the biggest private health companies on high alert to deliver crucial treatments such as cancer surgery should Omicron overwhelm National Health Service hospitals in England. The United Kingdom's death toll from the Covid-19 pandemic stands at 150,154, the world's seventh worst official Covid toll after the United States, Brazil, India, Russia, Mexico and Peru. Prime minister Boris Johnson has bet on refraining from lockdowns to deal with the Omicron variant which in recent weeks has swept across the UK, albeit with death rates significantly lower than previous waves. In a sign of just how stretched the NHS could become, health secretary Sajid Javid ordered England's NHS to strike a three-month deal with private health companies to allow patients to get treatments such as cancer surgery outside. "Millions of patients have already got their tests and treatment quicker thanks to our existing deal with independent providers," said David Sloman, NHS England chief operating officer and Covid incident director.

Loughborough-based generic and branded pharmaceutical manufacturer Morningside Pharmaceuticals has donated almost 60,000 packs of essential medicines to communities impacted by the war in Ukraine. The donation, which includes 1.29 million doses, was made after the company's founder and chairman, Dr Nik Kotecha OBE, spoke with the Ukrainian ambassador to the United Kingdom, Vadym Prystaiko, at a business event in London. Dr Kotecha, who was also recently appointed a deputy lieutenant of Leicestershire, said: "The heartbreaking situation in Ukraine has touched us all, and like so many people in the United Kingdom, we've been keen to do everything we can to help the victims of this terrible conflict." The large shipment of medicines has been transported in a secure and temperature controlled environment via Morningside's logistics partner to the embassy's distribution hub in Poland. From there the medicines will be supplied to hospitals, healthcare centres and patients throughout Ukraine including the regions hardest hit by the Russian invasion.

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

The Association of Independent Multiple Pharmacies (AIMp) has called upon all pharmacy organisations to unite and collectively represent the sector. While underlining the need for the sector to adopt a straightforward manifesto that can be presented to the public, politicians, and decision-makers, the association also advocated for a revitalisation of the 'Save Our Pharmacies' campaign, injecting it with renewed energy and a stronger sense of purpose. AIMp pointed out that a lack of cohesion is one of the factors contributing to the sector's struggle in gaining attention. "The current trajectory of community pharmacy is unsustainable," said Dr. Leyla Hannbeck, Chief Executive of AIMp. "To tackle the significant challenges ahead, we must work together cohesively. The most effective approach is to actively engage with Parliament, leveraging politicians from across the political spectrum to advocate for our cause." Meanwhile, the association urged various pharmacy bodies to unite in support of the Pharmacy All Party Parliamentary Group (APPG) to enhance its effectiveness and broaden its influence, rather than working independently.

French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide. The treatments will be provided under the new Impact brand, part of Sanofi's global health unit launched last year, which sits outside the commercial business. The plan also includes the $25 million Impact fund, which will go towards supporting local start-up healthcare businesses and providing training on using the medicines, Sanofi said. "There's a lot of noise at the moment from different companies jumping into this space… but investing in entrepreneurship, in the ecosystem, is a new thing," said Jon Fairest, who heads the global health unit. The treatments available are on the World Health Organization's essential medicines list, and insulin in particular has been singled out by the UN agency as a life-saving medicine for diabetics that is difficult to access in many lower-income countries, where the burden of disease is growing.

Monkeypox appears to be spreading from person to person in England, the UK Health Security Agency (UKHSA) said on Wednesday (June 1). The usually mild viral disease, which is endemic in west and central Africa, is understood to spread through close contact. Until early May, cases rarely cropped up outside Africa and were typically linked to travel to there. "The current outbreak is the first time that the virus has been passed from person to person in England where travel links to an endemic country have not been identified," the agency said. According to the UKHSA, the majority of cases in the United Kingdom - 132 - are in London, while 111 cases are known to be in gay, bisexual, or other men who have sex with men. Only two cases are in women. Recent foreign travel to a number of different countries in Europe within 21 days of symptom onset has been reported by 34 confirmed cases, or about 18 per cent of the 190 cases of the disease that have been confirmed by the United Kingdom as of May 31.

Northern Ireland will see changes in the regulatory landscape following the issuance of the Windsor Framework on 27th Feb 2023 and the corresponding EU Commission proposal. An agreement, in principle, has been reached by the UK and EU. The new path forward of the Windsor Framework marks a turning point in how both the UK and the EU will work together collaboratively and constructively to ensure that the same medicines are available in Northern Ireland at the same time as they are in the rest of the United Kingdom. Whilst this is a successful result for Northern Ireland patients, this is major change for companies that have made specific provisions in their supply chains for Northern Ireland. The supply chains of companies where provisions and changes were made such as introduction of GB specific pack may be impacted as a result. However, the burden on the UK Pharma supply chain will be eased. Prime Minister Rishi Sunak walks with European Commission chief Ursula von der Leyen in Windsor on February 27, 2023 Pharma companies will need to carefully consider making changes within their processes and supply chains pending the issuance of clear guidance from the MHRA on the regulation changes resulting from the Windsor Agreement and the corresponding EU Commission proposed regulatory changes associated with medicinal products within the Northern Ireland market. Smooth access to the EU market for Northern Ireland pharmaceutical and medical technology firms has been safeguarded within the constraints of the agreement. The pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee the supply of medicines within the whole United Kingdom.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries. This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain. Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company. Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines. Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

GlaxoSmithKline Pharmaceuticals Ltd is investing Rs 1,000 crore in a new state-of-the-art pharmaceutical unit in Karnataka ...

GlaxoSmithKline Pharmaceuticals Ltd is investing Rs 1,000 crore in a new state-of-the-art pharmaceutical unit in Karnataka ...

Novartis on Wednesday (February 1) predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4 per cent to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya. Novartis said it was on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its focus on its patented prescription medicines. Analysts have welcomed a programme unveiled in 2022 to trim costs and cut 8,000 jobs and plans to focus on fewer therapy areas and drug technologies. But the market has been underwhelmed by prospects for medium-term growth from new drugs.

The MHRA's Criminal Enforcement Unit (CEU), working with other law enforcement partners, has seized more than two million "illegally traded medicines" this year, with a total value of £5 million. The products confiscated in the UK were prescription-only medicines including anti-depressants, pain medication and human growth hormones. The MHRA launched an initiative, Operation Pangea, 15 years ago to combat "illegal internet trade in medical" products. Andy Morling, the Deputy Director of Criminal Enforcement of MHRA, spoke about Operation Pangea's 15-year anniversary. "Fifteen years ago, the MHRA started Operation Pangea, combining our knowledge and resources with those of international partners to disrupt and bring to justice the criminal gangs responsible for selling medicines illegally and causing harm around the world.

People need to understand the obesity-superspreader issue for the current COVID crisis and for the next one to come. The obese United States and other obese nations are in trouble at this point and poorly prepared for future viral events.

It was titled, "Prevalence of Unprofessional Social Media Content Among Young Vascular Surgeons," after which we saw many female physicians and surgeons from around the country posting pictures of themselves in a bikini, posing during relaxed evenings, or sitting beside the pool.